此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项名为 FGFR3 的基因发生变化的癌症患者的 LOXO-435 研究 (FORAGER-1)

2026年11月3日 更新者:Eli Lilly and Company

LOXO-435 (LY3866288) 在具有 FGFR3 改变的晚期实体瘤恶性肿瘤中的开放标签、多中心研究

The main purpose of this study is to learn more about the safety, side effects, and effectiveness of Vepugratinib by itself or when it is combined with other medicines that treat cancer. Vepugratinib may be used to treat cancer of the cells that line the urinary system and other solid tumor cancers that have a change in a particular gene (known as the FGFR3 gene). Study participation could last up to approximately 6 years, depending on which part of the study you join.

研究概览

详细说明

This is an open-label, multi-center, phase 1 study in participants with FGFR3-altered advanced solid tumor malignancy including metastatic urothelial cancer (UC), muscle-invasive bladder cancer (MIBC), and low grade intermediate risk non-muscle-invasive bladder cancer (LG IR NMIBC). The study will be conducted in 2 phases. Phase 1a will assess safety, tolerability, and pharmacokinetics of Vepugratinib to determine the optimal dose for further expansion. Phase 1b will include dose expansion cohorts to evaluate the efficacy and safety of Vepugratinib as monotherapy or in combinations with other medicines that treat cancer.

研究类型

介入性

注册 (估计的)

677

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  • 电话号码:1-317-615-4559
  • 邮箱:LillyTrials@Lilly.com

研究联系人备份

学习地点

      • Beijing、中国、100730
        • 招聘中
        • Beijing Hospital
      • Beijing、中国、100142
        • 招聘中
        • Beijing Cancer hospital
      • Guangdong、中国、510060
        • 招聘中
        • Sun Yat-Sen University- Cancer Center
      • Hangzhou、中国、310002
        • 招聘中
        • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
      • Hangzhou、中国、310003
        • 招聘中
        • Zhejiang Provincial People's Hospital
      • Shanghai、中国、200000
        • 招聘中
        • Renji Hospital, Shanghai Jiaotong University School of Medicine
      • Tianjin、中国、300060
        • 招聘中
        • Tianjin Medical University Cancer Institute & Hospital
      • Xi'an、中国、710061
        • 招聘中
        • The First Affiliated Hospital of Xi'an Jiaotong University
      • Petah Tikva、以色列、49100
        • 招聘中
        • Rabin Medical Center, Beilinson Hospital
      • Tel HaShomer、以色列、5265601
        • 招聘中
        • Sheba Medical Center
      • Toronto、加拿大、M5G 2M9
        • 招聘中
        • Princess Margaret Hospital
      • Vancouver、加拿大、V5Z 1J3
        • 招聘中
        • British Columbia Cancer Agency
      • Bonn、德国、53127
        • 尚未招聘
        • Universitaetsklinikum Bonn
      • München、德国、81675
        • 招聘中
        • Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
      • Tübingen、德国、72016
        • 招聘中
        • Universitaetsklinikum Tuebingen
      • Milan、意大利、20132
        • 招聘中
        • IRCCS Ospedale San Raffaele
      • Roma、意大利、00168
        • 招聘中
        • UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
      • Bergen、挪威、5021
        • 招聘中
        • Haukeland University Hospital
      • Oslo、挪威、0450
        • 招聘中
        • Oslo University Hospital
      • Chiba、日本、277-8577
        • 招聘中
        • National Cancer Center Hospital East
      • Nagoya、日本、464-8681
        • 招聘中
        • Aichi Cancer Center Hospital
      • Tokyo、日本、104-0045
        • 招聘中
        • National Cancer Center Hospital
      • Tokyo、日本、135-8550
        • 招聘中
        • Cancer Institute Hospital of JFCR
      • Bordeaux、法国、33076
        • 招聘中
        • Institut Bergonie
      • Lyon、法国、69373
        • 招聘中
        • Centre Leon Berard
      • Villejuif、法国、94805
        • 招聘中
        • Institut Gustave Roussy
      • Darlinghurst、澳大利亚、NSW 2010
        • 招聘中
        • St Vincent's Hospital
      • Hunter Region, NSW、澳大利亚、2310
        • 招聘中
        • Calvary Mater Newcastle
      • St Leonards、澳大利亚、2065
        • 招聘中
        • GenesisCare North Shore
      • Sydney、澳大利亚、2109
        • 招聘中
        • Macquarie University
    • Arizona
      • Tucson、Arizona、美国、85719
        • 招聘中
        • University of Arizona - Cancer Center
    • California
      • Duarte、California、美国、91010
        • 招聘中
        • City of Hope
      • Los Angeles、California、美国、90095
        • 招聘中
        • University of California, Los Angeles (UCLA) - Division of Hematology-Oncology
      • Orange、California、美国、92868
        • 招聘中
        • University of California - Irvine
      • Sacramento、California、美国、95817
        • 招聘中
        • University of California (UC) Davis Comprehensive Cancer Center
      • Stanford、California、美国、94305
        • 招聘中
        • Stanford Medicine Cancer Center
    • Florida
      • Orlando、Florida、美国、32804
        • 招聘中
        • Advent Health
    • Georgia
      • Atlanta、Georgia、美国、30322
        • 招聘中
        • Emory University Hospital
    • Illinois
      • Chicago、Illinois、美国、60637
        • 招聘中
        • The University of Chicago Medical Center (UCMC)
    • Indiana
      • Indianapolis、Indiana、美国、46202
        • 招聘中
        • Indiana University (IU) Melvin and Bren Simon Cancer Center
    • Louisiana
      • Baton Rouge、Louisiana、美国、70809
        • 招聘中
        • Mary Bird Perkins Cancer Center
      • New Orleans、Louisiana、美国、70121
        • 招聘中
        • Ochsner Clinic Foundation
    • Maryland
      • Baltimore、Maryland、美国、21231-2410
        • 招聘中
        • Johns Hopkins Kimmel Cancer Center
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • 招聘中
        • Massachusetts General Hospital
    • Michigan
      • Detroit、Michigan、美国、48201
        • 招聘中
        • Barbara Ann Karmanos Cancer Institute
    • Missouri
      • St Louis、Missouri、美国、63108
        • 招聘中
        • Washington University in St. Louis
    • New York
      • New York、New York、美国、10021
        • 招聘中
        • Weill Cornell Medicine
      • New York、New York、美国、10029
        • 招聘中
        • Icahn School of Medicine at Mount Sinai
      • New York、New York、美国、10032
        • 招聘中
        • Columbia University
      • New York、New York、美国、10065
        • 招聘中
        • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
      • New York、New York、美国、10016
        • 招聘中
        • New York University (NYU)
      • Rochester、New York、美国、14642
        • 招聘中
        • University of Rochester - Wilmot Cancer Institute
      • The Bronx、New York、美国、10467
        • 招聘中
        • Montefiore Medical Center
    • North Carolina
      • Chapel Hill、North Carolina、美国、27599
        • 招聘中
        • University of North Carolina (UNC) - Chapel Hill
    • Ohio
      • Cincinnati、Ohio、美国、45267
        • 招聘中
        • University of Cincinnati Medical Center (UCMC)
      • Columbus、Ohio、美国、43210
        • 招聘中
        • The Ohio State University (OSU)
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73104
        • 招聘中
        • University of Oklahoma - Health Sciences Center
    • Pennsylvania
      • Lancaster、Pennsylvania、美国、17601
        • 招聘中
        • Penn Medicine Lancaster General Hospital - Ann B. Barshinger Cancer Institute
      • Philadelphia、Pennsylvania、美国、19104
        • 招聘中
        • University of Pennsylvania
      • Philadelphia、Pennsylvania、美国、19107
        • 招聘中
        • Thomas Jefferson University
      • Pittsburgh、Pennsylvania、美国、15213
        • 招聘中
        • University of Pittsburgh Medical Center
      • Pittsburgh、Pennsylvania、美国、15212
        • 招聘中
        • Allegheny General Hospital
    • South Carolina
      • Myrtle Beach、South Carolina、美国、29572
        • 招聘中
        • Carolina Urologic Research Center
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • 招聘中
        • Tennessee Oncology
      • Nashville、Tennessee、美国、37212
        • 招聘中
        • Vanderbilt University Medical Center
      • Nashville、Tennessee、美国、37203
        • 招聘中
        • Sarah Cannon and HCA Research Institute
    • Texas
      • Dallas、Texas、美国、75244
        • 招聘中
        • University of Texas Southwestern
      • Dallas、Texas、美国、75251
        • 招聘中
        • Texas Oncology, P.A
      • Houston、Texas、美国、77030
        • 招聘中
        • MD Anderson Cancer Center
    • Utah
      • Salt Lake City、Utah、美国、84132
        • 招聘中
        • University of Utah
    • Vermont
      • Burlington、Vermont、美国、05401
        • 招聘中
        • University of Vermont Medical Center
      • Manchester、英国、M20 4BX
        • 招聘中
        • The Christie NHS Foundation Trust
      • Sheffield、英国、S10 2SB
        • 招聘中
        • Sheffield Teaching Hospitals NHS Foundation Trust
      • GE Rotterdam、荷兰、3015
        • 招聘中
        • Erasmus MC
      • Barcelona、西班牙、08908
        • 招聘中
        • Institut Catala d'Oncologia - L'Hospitalet
      • Madrid、西班牙、28041
        • 招聘中
        • Hospital Universitario 12 de Octubre
      • Madrid、西班牙、28050
        • 招聘中
        • South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC
      • Madrid、西班牙、28033
        • 招聘中
        • Fundacion MD Anderson International Espana
      • Santander、西班牙、39008
        • 招聘中
        • Hospital Universitario Marques De Valdecilla
      • Seoul、韩国、05505
        • 招聘中
        • Asan Medical Center
      • Seoul、韩国、03080
        • 招聘中
        • Seoul National University Hospital
      • Seoul、韩国、03722
        • 招聘中
        • Severance Hospital, Yonsei University Health System
      • Seoul、韩国、06351
        • 招聘中
        • Samsung Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Cohort A1, C1, D1, and D2: Locally advanced or metastatic solid tumor malignancy with a qualifying FGFR3 alteration.

  • Cohort A2, B2, B5 and B7: Urothelial cancer (UC) that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration.

  • Cohorts B1 and B4: Urothelial cancer that is locally advanced or metastatic and have received prior erdafitinib.

  • Cohort B6: Muscle Invasive Bladder Cancer with a qualifying FGFR3 alteration.

  • Cohort B7: Urothelial cancer that is locally advanced or metastatic with a qualifying FGFR3 genetic alteration and expression of human epidermal growth factor receptor 2 (HER2).

  • Cohort B8: Low Grade Intermediate Risk Non-Muscle Invasive Bladder cancer and a qualifying FGFR3 genetic alteration.

  • Measurability of disease:

    • Cohort A1, D1, and D2: Measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v 1.1 (RECIST v1.1).
    • Cohorts A2, B1, B2, B4, B5, B7, and C1: Measurable disease required as defined by RECIST v1.1.
    • Cohort B8: Baseline disease which includes at least 1 lesion.
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of:

    • 0 or 1 for Cohorts A1, A2, B5, B6, B7, and B8.
    • Less than or equal to 2 for Cohorts B1, B2, B4, C1, DI and D2.
  • Cohort B6: Must be eligible for radical cystectomy plus pelvic lymph node dissection and agree to undergo curative intent standard radical cystectomy plus pelvic lymph node dissection.

Exclusion Criteria:

  • Participants with primary central nervous system (CNS) malignancy.

  • Untreated or uncontrolled CNS metastases.

  • Current evidence of corneal keratopathy or retinal disorder. Individuals with asymptomatic ophthalmic conditions may be eligible.

  • Any serious unresolved toxicities from prior therapy.

  • Significant cardiovascular disease.

  • Prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF).

  • Active uncontrolled systemic infection or other clinically significant medical conditions.

  • Participants who are pregnant, lactating, or plan to breastfeed during the study or within 6 months of the last dose of study treatment. Participants who have stopped breastfeeding may be enrolled.

  • Cohort D1 only:

    • Have had renal transplantation.
    • Have a known history of nephrotic syndrome.
    • Have uncontrolled fluid overload, including clinically significant ascites, pleural effusion, or peripheral edema.
    • Have uncontrolled hypertension.
    • Are on hemodialysis or similar.
  • Cohort D2 only:

    • Have a history of:
    • Ventricular tachycardia or ventricular fibrillation.
    • Hypertrophic obstructive cardiomyopathy unless managed concurrently with atrial fibrillation.
    • Wolff-Parkinson-White syndrome.
    • Second- or third-degree atrioventricular block unless a functioning pacemaker is in place.
    • Heart rate less than (<) 50 bpm.
    • Have any of these medical conditions:
    • Severe respiratory insufficiency.
    • Sleep apnea syndrome.
    • Myasthenia gravis.
    • Acute narrow-angle glaucoma.
    • Active liver disease or clinically significant hepatic impairment.
    • History of myopathy or rhabdomyolysis with any HMG-CoA reductase inhibitor.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Phase 1a: Cohort A1 Vepugratinib Monotherapy Dose Escalation

Vepugratinib administered orally

Oral

其他名称:
  • LY3866288
  • LOXO-435
实验性的:Phase 1a: Cohort A2 Vepugratinib Monotherapy Dose Optimization

Vepugratinib administered orally

Oral

其他名称:
  • LY3866288
  • LOXO-435
实验性的:Phase 1b: Cohort B1, B2, B4, C1, and D1 Vepugratinib Monotherapy Dose Expansion

Vepugratinib administered orally

Oral

其他名称:
  • LY3866288
  • LOXO-435
实验性的:Phase 1b: Cohort B5 Vepugratinib Plus Pembrolizumab Plus Enfortumab Vedotin

Vepugratinib administered orally in combination with pembrolizumab administered IV and enfortumab vedotin administered IV

IV

Oral

其他名称:
  • LY3866288
  • LOXO-435

IV

实验性的:Phase 1b: MIBC Cohort B6 Vepugratinib Plus Pembrolizumab Plus Enfortumab Vedotin

Vepugratinib administered orally in combination with pembrolizumab administered IV and enfortumab vedotin administered IV

IV

Oral

其他名称:
  • LY3866288
  • LOXO-435

IV

实验性的:Experimental: Phase 1b: Cohort B7 Vepugratinib Plus Trastuzumab Deruxtecan

Vepugratinib administered orally in combination with trastuzumab deruxtecan administered IV

Oral

其他名称:
  • LY3866288
  • LOXO-435

IV

实验性的:Phase 1b: NMIBC Cohort B8 Vepugratinib Monotherapy Dose Expansion

Vepugratinib administered orally

Oral

其他名称:
  • LY3866288
  • LOXO-435
实验性的:Phase 1b: Cohort D2 (Drug to Drug Interaction)

Vepugratinib Plus Midazolam Plus Digoxin Plus Rosuvastatin (Lead-In Only) followed by Vepugratinib Monotherapy

Vepugratinib administered orally

Midazolam with digoxin with rosuvastatin administered orally once per cycle for 2 cycles.

Oral

其他名称:
  • LY3866288
  • LOXO-435

Oral

Oral

Oral

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Overall Response Rate (ORR)
大体时间:Up to Approximately 30 Months or 2.5 Years
Up to Approximately 30 Months or 2.5 Years
Pharmacokinetics (PK) of Vepugratinib: Area Under the Concentration versus Time Curve (AUC)
大体时间:Up to 2 Months
Up to 2 Months
PK of Midazolam, Rosuvastatin, and Digoxin Administered Alone and in the Presence of Vepugratinib: Area Under the Concentration versus Time Curve (AUC[0-inf])
大体时间:Up to 2 Months
Up to 2 Months
Complete Response Rate (CRR) in Participants with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG IR NMIBC)
大体时间:Up to approximately 24 months or 5 years
Up to approximately 24 months or 5 years

次要结果测量

结果测量
大体时间
Change from Baseline in Bladder-Related Symptoms, Measured by Functional Assessment of Cancer Therapy - Bladder (FACT-Bl) Subscale (BlCS)
大体时间:Cycle 1 Day 1, Cycle 2 Day 1, and Cycle 3 Day 1 (28 Day Cycles)
Cycle 1 Day 1, Cycle 2 Day 1, and Cycle 3 Day 1 (28 Day Cycles)
Change from Baseline in Physical Function, Measured by FACT- Physical Well-Being Scale (PWB) Subscale
大体时间:Up to Approximately 30 Months or 2.5 Years
Up to Approximately 30 Months or 2.5 Years
Event-Free Survival (EFS) in Participants with Muscle Invasive Bladder Cancer (MIBC)
大体时间:Up to approximately 30 months or 2.5 years
Up to approximately 30 months or 2.5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年1月12日

初级完成 (估计的)

2027年6月1日

研究完成 (估计的)

2027年6月1日

研究注册日期

首次提交

2022年11月7日

首先提交符合 QC 标准的

2022年11月7日

首次发布 (实际的)

2022年11月14日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅